Multinational biopharmaceutical firm, BioMarin, faced multiple IT challenges when the company contacted Sesame Software. With business critical data spread across offices in the United States, the United Kingdom, Hong Kong, Argentina, Brazil and Colombia, BioMarin needed to:
Efficiency of analysis and reporting is important to corporate operations.
The BioMarin IT team selected Sesame Software’s Relational Junction for Salesforce and Relational Junction ETL Manager because they are cost-effective, short-time-to-implement yet feature-rich data protection and integration solutions.
- Provides Salesforce data backup.
- Integrates disparate data repositories for coherent reporting for sales and marketing.
- Delivers consistent, integrated view of their customers to sales, marketing and customer service.
- Supplies key business automation and scheduling to reduce manual data analysis processes.
- Efficiently allows bidirectional integration of Salesforce CRM data with proprietary business information database, oracle ERP system and case management database for customer support.
- Cost-effective and straightforward to implement.
- Well-suited to BioMarin’s distributed multinational operational structure.
BioMarin is a multinational bio- pharmaceutical company that specializes in providing first-to-market therapeutics to patients with rare genetic diseases. BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
The company’s product portfolio comprises four marketed products and multiple clinical and pre-clinical product candidates. Marketed products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (currently approved in the EU only) (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6- sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU.
Evaluating the Options
The Relational Junction for Salesforce bidirectional data integration features have significantly enhanced BioMarin’s Salesforce usage and transformed their data management processes by eliminating redundant reporting and time-intensive, manual information capture.
BioMarin has been using Relational Junction for Salesforce for three years to automatically integrate information across departmental databases providing the sales, customer service and management teams with comprehensive and consistent information to fuel BioMarin’s business operations.